中国经济网北京5月19日讯 近日，长信基金公告，姚奕帆离任长信消费精选、长信医疗保健混合 （LOF）。 | 基金名称 | 长信医疗保健行业灵活配置混合型证券投资基金 | | --- | --- | | | (LOF) | | 基金简称 | 长信医疗保健混合(LOF) | | 基金主代码 | 163001 | | 基金管理人名称 | 长信基金管理有限责任公司 | | 公告依据 | 《公开募集证券投资基金信息披露管理办法》等 | | 基金经理变更类型 | 解聘基金经理 | | 共同管理本基金的其他基金经理姓名 | 京婕 | | 离任基金经理姓名 | 姚奕帆 | 姚奕帆2015年7月加入长信基金管理有限责任公司，历任量化研究员、量化专户投资经理、基金经 理助理，现任量化研究部基金经理。 （责任编辑：康博） 长信消费精选量化股票A成立于2018年3月7日，长信消费精选量化股票C成立于2021年8月12日，截 至2025年5月16日，其今年来收益率为-6.02%、-6.17%，累计收益率为3.30%、-46.73%，累计净值为 1.0330元、1.0174元。 长信医疗保健混合(LOF)A成立于2010年3月26日，长 ...

Core Insights - The majority of ordinary stock funds in China have performed well in the first seven months of the year, with 92% of the 983 funds showing positive returns [1] - The top-performing fund, Huaan Medical Biotechnology, achieved a remarkable increase of over 105% [1] - The strong performance of these funds is largely attributed to their heavy investments in the pharmaceutical sector, with several stocks experiencing significant gains [2][3] Fund Performance - Huaan Medical Biotechnology Fund A and C led the performance with increases of 105.40% and 104.88% respectively, heavily investing in companies like Innovent Biologics and Stone Pharma [1] - Other notable funds include Jiashi Mutual Selection and Fortune Medical Innovation, which saw increases of 97.28% and 96.67% respectively, also focusing on pharmaceutical stocks [2] - Funds with over 80% growth include Ping An Medical Selected Stocks and Penghua Medical Technology Stocks, indicating a strong trend in the healthcare investment space [3] Underperforming Funds - Only seven funds experienced declines exceeding 10%, primarily in sectors like consumer goods, new energy, and technology [4] - The Minsheng Plus Silver Preferred Stock Fund saw a decline of 13.06%, with major holdings in companies like CATL and BYD [4] - Other funds with significant declines include Changxin Consumer Selected Quantitative Stocks and Beixin Ruifeng Preferred Growth, both heavily invested in the liquor sector [5]